Wave Life Sciences, Duchenne muscular dystrophy
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.
Just as F1 teams rely on real-time data to optimize performance, IoT is enabling life sciences manufacturers to achieve new ...
Former Fed chairman Alan Greenspan coined the phrase "irrational exuberance" to describe the risk of unduly escalated asset ...
The Chicago battery startup announced plans to expand to Flint, Michigan, last week on the heels of a $60 million grant from ...
GlobalData on MSN1d
ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drugThe primary goals of the study are to evaluate the safety and overall response rate in patients who are given RLS-0071.
Five life sciences companies are expanding their operations in Connecticut, including several that are leasing space in the ...
Business Eye on MSN1d
Irish Life Sciences Start-Up Secures €280,000 Enterprise Ireland FundingMarama Labs, a life-sciences instrumentation start-up, has secured €280,000 in funding from Enterprise Ireland to fund the ...
By engaging with some of the most influential executives in the industry and the many organizations that advocate for them, the series will provide valuable perspectives on the evolving landscape of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback